Novartis (BOVESPA:N1VS34) - Cotización, noticias y análisis

Resumen acción N1VS34

Novartis AG se dedica a la investigación, desarrollo, fabricación y comercialización de productos sanitarios en Suiza y a escala internacional.

Acerca de la empresa

N1VS34 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	4/6
Financial Health	5/6
Dividends	4/6

Recompensas

Cotiza un 21.8% por debajo de nuestra estimación de su valor razonable

Los beneficios aumentaron un 41.6% el año pasado

Análisis de riesgos

El dividendo de 3.61% no está bien cubierto por los beneficios

Grandes partidas extraordinarias que afectan a los resultados financieros

Competidores de Novartis AG

Hypera

BOVESPA:HYPE3

R$18.6b

Roche Holding

SWX:ROG

CHF181.3b

AstraZeneca

LSE:AZN

UK£170.9b

Johnson & Johnson

NYSE:JNJ

US$355.7b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Novartis
Historical stock prices
Current Share Price	CHF48.75
52 Week High	CHF54.20
52 Week Low	CHF45.60
Beta	0.47
1 Month Change	-0.51%
3 Month Change	-8.59%
1 Year Change	0.52%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	14.52%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	N1VS34	BR Pharmaceuticals	Mercado BR
7D	1.9%	-6.5%	-4.5%
1Y	0.5%	-16.8%	11.1%

Rentabilidad vs. Industria: N1VS34 superó al sector BR Pharmaceuticals , que obtuvo un rendimiento del -25% el año pasado.

Rentabilidad vs. Mercado: N1VS34 obtuvo unos resultados inferiores a los del mercado BR, que fue del 17.7% el año pasado.

Volatilidad de los precios

Is N1VS34's price volatile compared to industry and market?
N1VS34 volatility
N1VS34 Average Weekly Movement	2.4%
Pharmaceuticals Industry Average Movement	5.5%
Market Average Movement	4.6%
10% most volatile stocks in BR Market	8.6%
10% least volatile stocks in BR Market	2.3%

Precio estable de las acciones: N1VS34 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de N1VS34 (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1996	76,057	Vas Narasimhan	www.novartis.com

Novartis AG se dedica a la investigación, desarrollo, fabricación y comercialización de productos sanitarios en Suiza y a escala internacional. La empresa ofrece medicamentos con receta para pacientes y médicos. Se centra en áreas terapéuticas como cardiovascular, renal y metabólica, inmunología, neurociencia y oncología, así como oftalmología y hematología.

Resumen de fundamentos de Novartis AG

¿Cómo se comparan los beneficios e ingresos de Novartis con su capitalización de mercado?
Estadísticas fundamentales de N1VS34
Capitalización bursátil	R$1.07t
Beneficios(TTM)	R$45.14b
Ingresos (TTM)	R$245.82b

24.2x

Ratio precio-beneficio (PE)

4.4x

Ratio precio-ventas (PS)

¿Está N1VS34 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de N1VS34
Ingresos	US$46.66b
Coste de los ingresos	US$12.02b
Beneficio bruto	US$34.64b
Otros gastos	US$26.07b
Beneficios	US$8.57b

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

Apr 23, 2024

Beneficios por acción (BPA)	3.91
Margen bruto	74.24%
Margen de beneficio neto	18.36%
Ratio deuda/patrimonio	52.6%

¿Cómo se ha desempeñado N1VS34 a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

3.8%

Rentabilidad actual por dividendo

95%

Ratio de pagos

Resumen acción N1VS34

Recompensas

Análisis de riesgos

Competidores de Novartis AG

BOVESPA:HYPE3

R$18.6b

SWX:ROG

CHF181.3b

LSE:AZN

UK£170.9b

NYSE:JNJ

US$355.7b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Recent updates

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Novartis AG Provides Earnings Guidance for the Year 2024

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G)

Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer

Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH

Novartis AG to Report Q4, 2023 Results on Jan 31, 2024

Novartis Announces New Positive Data from the Phase III REMIX-1 and REMIX-2 Studies Investigating Remibrutinib

Novartis Announces US Food and Drug Administration Approves Cosentyx® to Treat Moderate to Severe Hidradenitis Suppurativa in Adults

Novartis Announces Positive Topline Results from the Interim Analysis of the Ongoing Pivotal Phase III ALIGN Study

Novartis AG Announces Impairment Charges for the Third Quarter of 2023

Novartis AG Raises Earnings Guidance for the Fiscal Year 2023

Novartis Kisqali Natalee Analysis Confirms Consistent Reduction in Risk of Recurrence Across Key Sub Groups of Patients with Early Breast Cancer

FDA Approves Novartis Cosentyx® as First Intravenous (Iv) Formulation Interleukin-17A Antagonist for Rheumatic Diseases

Novartis to Present New Oncology Data at ESMO 2023 Demonstrating Practice-Changing Innovation in Advanced Prostate and Early Breast Cancer

Novartis AG completed the Spin-Off of Sandoz Group AG (SWX:SDZ).

Bausch & Lomb Ireland completed the acquisition of ophthalmology assets of Novartis AG from Novartis AG for $2.5 billion.

Sandoz, Novartis Division, Receives European Commission Approval for Tyruko (Natalizumab), First and Only Biosimilar for Multiple Sclerosis in Europe

Novartis Radioligand Therapy Lutathera® Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival in First Line Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Novartis AG Issues Voluntary Nationwide Recall of One Lot of Sandimmune Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization

Novartis AG Announces Executive Changes

Novartis Presents New Long-Term Leqvio (Inclisiran) Data Demonstrating Consistent Efficacy and Safety Beyond Six Years

Sandoz Announces Positive Results from Mylight Phase III Study for Biosimilar Aflibercept

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Novartis Ag Announces Positive Top-Line Results from the Phase Iii Remix-1 and Remix-2 Studies Evaluating Remibrutinib 25 Mg B.I.D

Novartis AG (SWX:NOVN) acquired DTx Pharma, Inc. for $1 billion.

US FDA Approves Expanded Indication for Novartis Leqvio® (Inclisiran) to Include Treatment of Adults with High LDL-C and Who Are at Increased Risk of Heart Disease

Bausch + Lomb Corporation (NYSE:BLCO) signed an agreement to acquire ophthalmology assets from Novartis AG (SWX:NOVN) for $2.5 billion.

Novartis AG (SWX:NOVN) entered into an agreement to acquire Chinook Therapeutics, Inc. (NasdaqGS:KDNY) for approximately $2.8 billion.

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Novartis AG

24.2x

4.4x

Beneficios e Ingresos

Dividendos

3.8%

95%